This trial is unknown status.

Condition cocaine-related disorders
Treatment tolcapone
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date July 2001
End date March 2002
Trial size 16 participants
Trial identifier NCT00033059, NCT00024765, NIDA-CTO-0003-1


The purpose of this study is to assess the potential interactions between intravenous (IV) cocaine and tolcapone.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Masking double-blind
Primary purpose treatment

Primary Outcomes

time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: Volunteers dependent on cocaine and are non-treatment seeking; between 18-45 yrs of age; DSM-4 criteria for cocaine abuse or dependence Exclusion Criteria: Additional criteria available during screening at the site

Additional Information

Official title Assessment of Potential Interactions Between Intravenous Cocaine and Tolcapone
Principal investigator Thomas Newton, M.D.
Description Double-blind, inpatient study by screening responses to cocaine infusions of 20 and 40 mg i.v. subjects into 1 of 2 treatment groups to assess potential interactions between i.v. cocaine infusion and treatment with tolcapone.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).